- Home
- WLK vs MRNA Comparison
WLK vs MRNA Comparison
Compare WLK & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLK
- MRNA
- Stock Information
- Founded
- WLK 1986
- MRNA 2010
- Country
- WLK United States
- MRNA United States
- Employees
- WLK N/A
- MRNA N/A
- Industry
- WLK Major Chemicals
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLK Industrials
- MRNA Health Care
- Exchange
- WLK Nasdaq
- MRNA Nasdaq
- Market Cap
- WLK 10.1B
- MRNA 9.2B
- IPO Year
- WLK 2004
- MRNA 2018
- Fundamental
- Price
- WLK $62.57
- MRNA $24.62
- Analyst Decision
- WLK Buy
- MRNA Hold
- Analyst Count
- WLK 16
- MRNA 15
- Target Price
- WLK $92.31
- MRNA $36.69
- AVG Volume (30 Days)
- WLK 1.3M
- MRNA 12.2M
- Earning Date
- WLK 10-30-2025
- MRNA 11-06-2025
- Dividend Yield
- WLK 3.39%
- MRNA N/A
- EPS Growth
- WLK N/A
- MRNA N/A
- EPS
- WLK N/A
- MRNA N/A
- Revenue
- WLK $11,480,000,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- WLK N/A
- MRNA N/A
- Revenue Next Year
- WLK $3.14
- MRNA $10.38
- P/E Ratio
- WLK N/A
- MRNA N/A
- Revenue Growth
- WLK N/A
- MRNA N/A
- 52 Week Low
- WLK $62.30
- MRNA $23.04
- 52 Week High
- WLK $133.51
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- WLK 29.60
- MRNA 45.38
- Support Level
- WLK $62.30
- MRNA $23.04
- Resistance Level
- WLK $65.68
- MRNA $27.10
- Average True Range (ATR)
- WLK 2.69
- MRNA 1.61
- MACD
- WLK -0.44
- MRNA -0.02
- Stochastic Oscillator
- WLK 1.51
- MRNA 26.54
About WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.